License Agreements - Additional Information (Details) $ / shares in Units, € in Millions	1 Months Ended	3 Months Ended		6 Months Ended			12 Months Ended
	Jan. 31, 2020 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) Item shares	Jun. 30, 2024 EUR (€) Item	Jun. 30, 2023 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2012 Item	Dec. 31, 2023 USD ($) shares	Jan. 09, 2020 USD ($) $ / shares
Research And Development Arrangement Contract To Perform For Others [Line Items]
Number of common shares | shares		47,801,578		47,801,578					47,351,363
Value of common stock		$ 5,000		$ 5,000					$ 5,000
Research and development expense recognized		49,853,000	$ 20,581,000	86,683,000		$ 38,374,000
License Agreement | Antecip
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments or royalties		2,000,000	800,000	3,600,000		1,300,000
Accrued royalty payments		3,600,000	1,300,000	$ 3,600,000		1,300,000
Number of exclusive license agreements | Item				3	3			3
License agreement royalty as a percent of net sales				3.00%	3.00%
License agreement royalty, maximum reduction percent as a result of required third party payments								50.00%
License agreement term, from first commercial sale								10 years
License Agreement | Antecip | AXS-05
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement royalty as a percent of net sales								3.00%
License Agreement | Antecip | Other Two Products | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement royalty as a percent of net sales								1.50%
License Agreement | Antecip | Other Two Products | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement royalty as a percent of net sales								4.50%
Pfizer Inc | License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Number of common shares | shares	82,019
Value of common stock	$ 8,000,000
Prior trading days	10 days
Share price | $ / shares	$ 97.54
Upfront cash payment	$ 3,000,000
Fair value share price | $ / shares										$ 87.24
Fair value of common stock										$ 7,200,000
Research and development expense recognized							$ 10,200,000
Future milestone payments		323,000,000		$ 323,000,000
Milestone payments or royalties		0	0	0		0
Pharmanovia | License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non-refundable upfront payment received				65,700,000	€ 62.0
Eligible to receive sales-based and other milestones | €					€ 94.5
Royalty revenue		$ 600,000	$ 700,000	1,500,000		1,000,000
Other development and sales based milestones recognized				$ 0		$ 0